ACUT (Accustem Sciences) Short Interest


ACUT Accustem Sciences Inc ACUT
27 GF Score
Price $0.19
! 1 Warning Sign
View Full Analysis

What is Accustem Sciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ACUT vs DCOY, BIXT, SPRC: Short Interest Comparison

For the Biotechnology subindustry, Accustem Sciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accustem Sciences Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Short Interest falls into.


ACUT
27GF Score
Accustem Sciences Inc ACUT
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accustem Sciences Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10001
Accustem Sciences Inc is a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people who are diagnosed with cancer each year. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services.
27GF Score

Get the complete analysis for ACUT

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price